Anti-(human Proprotein Convertase Subtilisin/kexin Type 9) (human Monoclonal Ibi306 .gamma.2-chain)
Anti-(human Proprotein Convertase Subtilisin/kexin Type 9) (human Monoclonal Ibi306 .gamma.2-chain) Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-(human Proprotein Convertase Subtilisin/kexin Type 9) (human Monoclonal Ibi306 .gamma.2-chain) is under investigation in clinical trial NCT04031742 (A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia).
| Trade Name | Anti-(human Proprotein Convertase Subtilisin/kexin Type 9) (human Monoclonal Ibi306 .gamma.2-chain) |
| Generic | Tafolecimab |
| Tafolecimab Other Names | Immunoglobulin igg2, anti-(human proprotein convertase subtilisin/kexin type 9) (human monoclonal ibi306 .gamma.2-chain), disulfide with human monoclonal ibi306 .kappa.-chain, dimer, Tafolecimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Anti-(human Proprotein Convertase Subtilisin/kexin Type 9) (human Monoclonal Ibi306 .gamma.2-chain)
